Search
-
Boan Biotech’s Broad-Spectrum Neutralizing Antibody BA-CovMab Injection Approved for Clinical Trials in China
Shanghai, September 12, 2022 – BA-CovMab injection, the broad-spectrum neutralizing antibody developed by Luye Pharma Group subsidiary Boan Biotech for use against severe acute respiratory syndr...
2022-09-13
MORE>
-
Boan Biotech’s Investigational Anti-CD25 Antibody BA1106 Approved for the First Clinical Trial on Treating Solid Tumors in China
Shanghai, September 7, 2022 - Luye Pharma Group announced today that BA1106, a human anti-CD25 monoclonal antibody developed by its subsidiary Boan Biotech, has been approved for clinical trials by th...
2022-09-08
MORE>
-
New Drug Application for the New Indication of Breast Cancer Accepted in China for Luye Pharma's Goserelin Microspheres
August 15, 2022 - Luye Pharma Group today announced that the New Drug Application (NDA) for its Goserelin Acetate Extended-release Microspheres for Injection (LY01005) for the treatment of breast canc...
2022-08-16
MORE>
-
Luye Pharma’s Innovative Formulation Goserelin Acetate Extended-Release Microspheres for Injection Meets Primary Endpoints in Phase III Clinical Trial for the Treatment of Breast Cancer
Shanghai, July 24, 2022 — Luye Pharma Group announced today that its investigational drug Goserelin Acetate Extended-Release Microspheres for Injection (LY01005) for the treatment of breast cancer ha...
2022-07-25
MORE>
-
Luye Pharma’s Innovative Formulation LY03003 Meets Primary Endpoints in Phase III Clinical Trial for Treating Parkinson’s Disease
July 19, 2022 - Luye Pharma Group announced today that its investigational drug Rotigotine Extended-release Microspheres for Injection (LY03003) has met the expected endpoints in a phase III clinical ...
2022-07-20
MORE>
-
Luye Pharma’s Innovative Drug Lurbinectedin Approved for Urgent Clinical Use in Hainan
Shanghai, July 17, 2022 — Luye Pharma Group today announced that Lurbinectedin, an innovative anticancer drug, has been approved by the Hainan Medical Products Administration for urgent clinical use ...
2022-07-18
MORE>
-
Phase III Clinical Trial Results of Luye Pharma’s Investigational Drug LY03005 Presented at the 2022 APA Annual Meeting
The Phase III clinical trial results of Luye Pharma’s investigational drug LY03005, designated as a “Class 1 Chemical Drug” in China, were presented at the 2022 Annual Meeting of the American ...
2022-06-09
MORE>
-
Marketing Authorization Application for Luye Pharma’s Rivastigmine Twice Weekly Transdermal Patch Accepted in China
Shanghai, China, April 12, 2022 — Luye Pharma Group announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Marketi...
2022-04-14
MORE>
-
Luye Pharma Grants Exeltis Exclusive Commercialization Rights to Its Innovative Alzheimer’s Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Mexico and Poland
Basel, Switzerland, March 31, 2022 – Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into agreements with Exeltis Pharma México,...
2022-04-01
MORE>
-
Luye Pharma’s LY03005 Approved by China’s CDE to Conduct Phase III Clinical Trial for the Treatment of Generalized Anxiety Disorder
Shanghai, China, March 21, 2022 – Luye Pharma Group announced today that its investigational drug, LY03005, has received approval from the Center for Drug Evaluation (CDE) at China's Nationa...
2022-03-22
MORE>
var _hmt = _hmt || [];
(function() {
var hm = document.createElement("script");
hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864";
var s = document.getElementsByTagName("script")[0];
s.parentNode.insertBefore(hm, s);
})();
!function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7iMpaU8NS42Fm",ck:"K9y7iMpaU8NS42Fm"});
one体育-艾尚体育
沐鸣平台_沐鸣平台科技_沐鸣平台厂家_沐鸣平台企业
力量体育app_官网-力量体育app
one体育-官网app下载
im电竞官网app